RxDoctor Payments Data

Sharonda Washington

Family · Indianapolis, INNPI 1396427811

Payments from drug & device makers

$3,247in general payments, 2019–2025

Across 153 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ANI Pharmaceuticals, Inc.$760
  • AbbVie$672
  • Pfizer$267
  • Boston Scientific$240
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$235
  • Lundbeck LLC$187
  • plus $886 from 18 others

What the payments were for

  • Food & beverage$3,240100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,247 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$42,886
Medicare patients
145
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl32$22,996
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen633$15,390
OxycontinOxycodone Hcl30$12,303
ZubsolvBuprenorphine Hcl/Naloxone Hcl14$11,144
Buprenorphine33$10,766
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl53$10,392
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen330$10,261
Fentanyl44$3,483
Lidocaine21$2,085
Pregabalin96$1,766
Oxycodone Hcl73$1,552
Morphine Sulfate ErMorphine Sulfate40$1,486
Gabapentin128$1,187
Tramadol Hcl56$905
Celecoxib31$738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$61$22,99632 claims
Orexo US, Inc.Zubsolv$17$11,14414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →